We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

68 hedge funds and large institutions have $612M invested in ArriVent BioPharma in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,167% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 3

700% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 2

51% more capital invested

Capital invested by funds: $404M → $612M (+$208M)

26% more funds holding

Funds holding: 54 → 68 (+14)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

12.48% more ownership

Funds ownership: 64.66% → 77.13% (+12%)

Holders
68
Holders Change
+14
Holders Change %
+25.93%
% of All Funds
0.98%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
16
Increased
38
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$28.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$15.8M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.22M
4
State Street
State Street
Massachusetts
+$7.34M
5
Millennium Management
Millennium Management
New York
+$4.64M

Top Sellers

1
AA
AlphaCentric Advisors
Puerto Rico
-$1.61M
2
HLAM
Hidden Lake Asset Management
New York
-$689K
3
Walleye Capital
Walleye Capital
New York
-$464K
4
Jane Street
Jane Street
New York
-$107K
5
TRCT
Tower Research Capital (TRC)
New York
-$29.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
HA
1
HHLR Advisors
Cayman Islands
$105M – – –
O
2
OrbiMed
New York
$71.1M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$49.8M +$3.85M +169,514 +9%
OCA
4
Octagon Capital Advisors
New York
$46.4M +$3.93M +173,083 +10%
BlackRock
5
BlackRock
New York
$45.4M +$28.8M +1,268,154 +191%
SCM
6
Suvretta Capital Management
New York
$43.4M +$3.01M +132,459 +8%
SI
7
Sofinnova Investments
California
$39.9M – – –
NHAS
8
Novo Holdings A/S
Denmark
$35.4M +$121K +5,315 +0.4%
GCGM
9
General Catalyst Group Management
Massachusetts
$35.1M – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$31.6M +$15.8M +694,476 +107%
HH
11
HSG Holding
Hong Kong
$19M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$14M +$8.22M +362,221 +154%
CAM
13
Cormorant Asset Management
Massachusetts
$13.8M +$1.6M +70,462 +14%
State Street
14
State Street
Massachusetts
$11.2M +$7.34M +323,186 +210%
PA
15
Perceptive Advisors
New York
$9.75M – – –
Northern Trust
16
Northern Trust
Illinois
$5.42M +$3.46M +152,321 +195%
Millennium Management
17
Millennium Management
New York
$5.09M +$4.64M +204,527 +1,690%
Charles Schwab
18
Charles Schwab
California
$4.76M +$2.78M +122,641 +154%
Morgan Stanley
19
Morgan Stanley
New York
$3.94M +$2.87M +126,350 +305%
WP
20
Woodline Partners
California
$2.84M +$475K +20,944 +21%
Marshall Wace
21
Marshall Wace
United Kingdom
$2M +$1.94M +85,250 New
Goldman Sachs
22
Goldman Sachs
New York
$1.71M +$1.66M +72,968 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.61M +$873K +38,474 +129%
GCM
24
Ghisallo Capital Management
Massachusetts
$1.18M – – –
SVCM
25
Saturn V Capital Management
Texas
$1.11M +$1.07M +47,266 New
1
2 3

AVBP Hedge Fund Activity: Q3 2024 in Review

68 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q3 2024, worth a combined $612M — up 51% from $404M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVBP positions and 2 closed out — a net gain of 14 holders — while 38 added to existing stakes and 3 trimmed.

The largest buyer was BlackRock, adding an estimated $28.8M. The largest seller was AlphaCentric Advisors, cutting an estimated $1.61M.

  • 68 institutional investors held ArriVent BioPharma (AVBP) as of Q3 2024, up from 54 in Q2 2024.
  • Funds reported $612M of ArriVent BioPharma stock for Q3 2024, up 51% quarter-over-quarter.
  • 16 funds opened new ArriVent BioPharma positions in Q3 2024 and 2 closed out, a net change of +14 holders.
  • The largest ArriVent BioPharma buyer in Q3 2024 was BlackRock, an estimated $28.8M added.
  • The largest ArriVent BioPharma seller in Q3 2024 was AlphaCentric Advisors, an estimated $1.61M sold.

Based on aggregated 13F filings for Q3 2024.